NASDAQ · SLSN

Solesence, Inc.

$0.94 -$0.06 (-5.54%) 1D Market open

Key Metrics

$70.29M
Market cap
74.46×
P/E · TTM
$60.40M
Revenue · TTM
$944.00K
Net income
EPS · TTM $0.01
Dividend yield
Free cash flow
Beta · 1Y 2.35
EBITDA · TTM $2.00M
Gross margin 26.5%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved +29.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Jul 14
    From its May 11 high, the share price fell 57%.

    Peak close $1.50 on May 11; trough close $0.64 on Jul 14. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -57%
  • Apr 2
    The stock moved +30.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$70.29M
Enterprise value
Shares outstanding70.6M
52-wk range$0.61 – $4.55
Avg volume · 20D89.1K
Net cash
Book value / share$0.23
IndustryPerfumes, Cosmetics & Other Toilet Preparations
ExchangeNASDAQ
About Solesence, Inc.
IPO dateNov 26, 1997
Employees115

Solesence Inc is a health-oriented, science-driven company, focused on various skin health, beauty and wellness markets.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E74.46
P/S1.16
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.26

Profitability

Gross 26.5%
Operating 1.7%
Net 1.6%
FCF
ROE / ROIC 5.9% · —

Financial Health

Current ratio2.08
Quick ratio0.70
Debt / equity
Debt / EBITDA
Net cash
Working capital$13.72M

Cash Flow · TTM

Operating CF $171.00K
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

$0.26 vs $0.94
Trades 3.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings